Themes 2020

The Central Nervous System

Health Care Sector Icon

Why are you expecting big advances in the treatment of central nervous system diseases over the next few years?

The greatest biotech treatment advances of the next five or ten years are expected to occur in neuroscience, with novel treatments under development in SMA, Huntington’s, Autism, ALS, DMD, Parkinson’s and Alzheimer’s.

Recent reorganization of the FDA includes establishment of an Office of Neuroscience, driven by FDA’s focus on the great unmet need in this area, and an upcoming wave of new high-technology drug candidate reviews. Given the paucity of treatment options for diseases such as Alzheimer’s, any safe and effective therapy that makes it to market would be widely adopted.

What we’re watching:

  • Biogen’s aducanumab data
  • Roche’s gantenerumab and anti-tau trials
  • FDA regulatory flexibility
  • FDA Office of Neuroscience
Themes 2020

15 Themes to Focus on 2020: A Handbook for Portfolio Managers

Download the Handbook

People in us suffering from Alzheimer’s


Meetings of FDA’s peripheral central nervous system drugs advisory committee in 2019


Estimated US TAM for Aducanumab if approved


Alzheimer’s drugs that have failed in previous clinical trials


A Strategic Review Of The State Of The Capital Markets In Q4 2022 & A Look Toward 2023

Read More >
Representing the shift to cloud technology is a blue network foregrounding the blue webscape that is the internet.
Ahead of the Curve®

Telco vs. Cloud and Private Networks

Read More >
Representing IT services, and Identity and Access Management is a blue network foregrounding the blueish and yellow surface of a computer chip containing a finger print.
Ahead of the Curve®

Despite Macro, Identity & Access Management Remains Resilient

Read More >


New York, NY

Jun 06, 2023

7th Annual Future of the Consumer Conference

Learn More >
Boston, MA

Mar 06, 2023

43rd Annual Health Care Conference

Learn More >
Arlington, VA

Feb 15, 2023

44th Annual Aerospace/Defense & Industrials Conference

Learn More >